在患有早期症状性阿尔茨海默氏病的美国参与者中进行多纳单抗 (LY3002813) 加常规护理与单独常规护理的真实世界比较研究
多纳单抗加常规护理与单独常规护理对美国早期症状性阿尔茨海默氏病患者的长期实际疗效比较 (TRAILBLAZER-REAL US)
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- 电话号码:1-317-615-4559
- 邮箱:clinical_inquiry_hub@lilly.com
学习地点
-
-
Alabama
-
Huntsville、Alabama、美国、35805-4046
- 招聘中
- Rehabilitation & Neurological Services
-
首席研究员:
- Belinda Savage-Edwards
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study population will consist of a donanemab plus usual care group and a usual care alone group. Participants will be enrolled 1:2 into donanemab plus usual care and usual care alone groups to allow enough participants in the usual care group to be matched with participants in the donanemab group to enable robust comparative effectiveness analyses.
描述
Inclusion Criteria:
Participants
- are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records [EHR] is required prior to screening)
- have a Telephone Interview for Cognitive Status (TICS) score of ≥21
- presence of amyloid beta (Aβ) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid [CSF]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)
- have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and
- have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.
Exclusion Criteria:
- have prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)
- have current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (>12 months) institutional-level care, serious psychiatric illness, etc.)
- are currently enrolled or intend to enroll in a clinical trial of another investigational product, and
- have contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Donanemab Group + Usual Care
Participants will receive open-label (unblinded) donanemab intravenously (IV) and Usual Care |
Administered IV
其他名称:
Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting. |
|
Usual Care Group
Participants will receive usual care. |
Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to First Increase in Dependence Level Above Baseline (as derived from the Dependence Scale [DS])
大体时间:Up to 5 Years
|
The DS is a caregiver-reported outcome assessing the need for daily in-home or institutional assistance by participants with AD. The DS is completed as a structured interview with a knowledgeable caregiver or study partner. The scale is composed of 13 items evaluating progressive needs for assistance. The total score ranges from 0 to 15, with higher scores indicating a greater degree of dependence on external support. |
Up to 5 Years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
基线时依赖程度 <3 的参与者子组失去独立性的时间(根据 DS 得出的依赖程度≥3)
大体时间:长达 5 年
|
长达 5 年
|
|
|
DS 总分随时间(每半年)相对基线的变化
大体时间:基线,长达 5 年
|
基线,长达 5 年
|
|
|
由 P-LSQ 评估的家庭医疗保健随时间推移(每半年评估一次)相对于基线的变化
大体时间:基线,长达 5 年
|
基线,长达 5 年
|
|
|
由 P-LSQ 评估的驾驶状况随时间推移(每半年评估一次)相对于基线的变化
大体时间:基线,长达 5 年
|
基线,长达 5 年
|
|
|
Time to Institutionalization from Baseline for the Subgroup of Participants not Institutionalized at Baseline
大体时间:Up to 5 Years
|
Participants who endorse, "Assisted living facility" or "Skilled nursing facility, nursing home, hospice" as their primary residence on the participant lifestyle status Questionnaire (P-LSQ) will be considered institutionalized. |
Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Semi-Annually) in Functional Assessment Questionnaire (FAQ) Total Score
大体时间:Baseline, Up to 5 Years
|
The FAQ is a brief, 10-item caregiver-reported outcome measure assessing performance on functional activities impacted early during AD. The maximum total score is 30, with higher scores indicating greater impairment. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Yearly) in Neuropsychiatric Inventory (NPI-Q) Total Severity Score
大体时间:Baseline, Up to 5 Years
|
The NPI-Q is a brief, caregiver-reported assessment of neuropsychiatric symptoms associated with dementia. The NPI-Q yields total scores for Severity and Distress, reflecting the sum of ratings across all domains, with higher scores indicating a greater degree of symptom severity and caregiver distress, respectively. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Yearly) in Zarit Burden Inventory-short version (ZBI-12) total score
大体时间:Baseline, Up to 5 Years
|
ZBI is a caregiver-reported instrument used widely to evaluate caregiver burden associated with AD and other diseases such as multiple sclerosis, congestive heart failure, and cancer. Items on the ZBI-12 assess caregiver stress, time available for self, and the impact of caring on the caregiver's social life. Responses are provided on a 5-point Likert scale (never=0, nearly always=4). The ZBI-12 total score has a range of 0 to 48, with higher scores indicating greater caregiver burden. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Semi-Annually) in Living Situation as Assessed by the Participant Lifestyle Questionnaire (P-LSQ)
大体时间:Baseline, Up to 5 Years
|
The P-LSQ is a brief, sponsor-created questionnaire used to collect supplementary data regarding participants' living environment, home healthcare needs, and driving status that is not captured elsewhere. |
Baseline, Up to 5 Years
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 18721
- I5T-MC-AACS (其他标识符:Eli Lilly and Company)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 共享时间框架
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.